Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial (Q37030111)

17 August 2017

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial (English)

1 reference

non-small-cell lung carcinoma

17 August 2017

phase II clinical trial

0 references

1 reference

Koichi Takayama

1

1 reference

17 August 2017

Nobuyuki Katakami

2

1 reference

17 August 2017

Takuma Yokoyama

3

1 reference

17 August 2017

Shinji Atagi

4

1 reference

17 August 2017

Kozo Yoshimori

5

1 reference

17 August 2017

Hiroshi Kagamu

6

1 reference

17 August 2017

Hiroshi Saito

7

1 reference

17 August 2017

Yuichi Takiguchi

8

1 reference

17 August 2017

Keisuke Aoe

9

1 reference

17 August 2017

Akira Koyama

10

1 reference

17 August 2017

Naoyuki Komura

11

1 reference

17 August 2017

Kenji Eguchi

12

1 reference

17 August 2017

23 March 2016

1 reference

Supportive Care in Cancer

17 August 2017

1 reference

17 August 2017

24

1 reference

17 August 2017

3495-3505

1 reference

17 August 2017

8

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

17 August 2017

start time

23 March 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00520-016-3144-z

0 references

cites work

Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Treatment of cachexia: an overview of recent developments

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Megestrol acetate for treatment of anorexia-cachexia syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Understanding the mechanisms and treatment options in cancer cachexia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Cachexia as a major underestimated and unmet medical need: facts and numbers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

ABC of palliative care. Anorexia, cachexia, and nutrition

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Body-composition changes in patients who gain weight while receiving megestrol acetate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

A nonpeptidyl growth hormone secretagogue

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Clinical Symptoms and Length of Survival in Patients With Terminal Cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Japanese version of the MD Anderson Symptom Inventory: a validation study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Ghrelin enhances appetite and increases food intake in humans

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917578

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-016-3144-Z

Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27005463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27005463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00520-016-3144-Z

1 reference

17 August 2017

1 reference

17 August 2017

1 reference